

Tetrahedron 55 (1999) 14803-14806

TETRAHEDRON

A Facile Synthesis of Flumazenil Analogues

Gianluigi Broggini,*^a Giorgio Molteni,^b Alberto Terraneo^b and Gaetano Zecchi^a

⁴Università dell'Insubria, Dipartimento di Scienze Chimiche, Fisiche e Matematiche, via Lucini 3, 22100 Como, Italy

^b Università di Milano, Dipartimento di Chimica Organica e Industriale, via Golgi 19, 20133 Milano, Italy

Received 2 August 1999; revised 30 September 1999; accepted 14 October 1999

Abstract: A number of 8-substituted 5-methyl[1,2,3]triazolo[1,5-a][1,4] benzodiazepin-6(4H)-ones (6) were synthesised in a concise and efficient way starting from isatoic anhydrides and exploiting an intramolecular azide cycloaddition. © 1999 Published by Elsevier Science Ltd. All rights reserved.

1,4-Benzodiazepines fused to a five-membered heterocycle occupy a prominent place among drugs for the treatment of CNS disturbances.¹⁻⁵ For instance, alprazolam 1 is a common anxiolytic agent,⁶ while flumazenil 2 belongs to the family of cognition enhancers.⁷



Within our research into heterocyclic syntheses by means of intramolecular 1,3-dipolar cycloadditions of the azido group,^{8,9} we have developed a facile entry to a series of 8-substituted 5-methyl-[1,2,3]triazolo[1,5-a][1,4]benzodiazepin-6(4H)-ones 6, the structure of which is closely related to that of flumazenil.

Results and Discussion

Our synthetic approach started from the reaction of 5-substitued isatoic anhydrides 3 with the commercially available methylpropargylamine (Scheme 1). The reaction was carried out in boiling dioxane in the case of 3a and in boiling DMF in the case of the less reactive substrates 3b-d, to give the anthranilamides 4 in 44-54% yield. These were subjected to diazotization and subsequent reaction of the intermediate diazonium salts with sodium azide. The expected azides 5 were not isolable as intramolecular cycloaddition onto the acetylenic bond occurred spontaneously *in situ*, and simple evaporation of the solvent led to the final targets 6. The overall yields of 41-55% in this cascade-type reaction sequence from 4 are preparatively useful. Further in order to widen the variety of the targets, the nitro derivate 6d was converted into the corresponding amino derivative 6e via catalytic hydrogenation.

0040-4020/99/\$ - see front matter @ 1999 Published by Elsevier Science Ltd. All rights reserved. PII: S0040-4020(99)00944-8



The toxicological and pharmacological properties of the tricyclic compounds 6a-e are under evaluation.

Experimental Section

M.p. were determined on a Büchi apparatus and are uncorrected. IR Spectra were recorded on a FT-IR Perkin-Elmer 1725X spectrophotometer. ¹H-NMR and ¹³C-NMR spectra were taken using a Bruker 300 MHz apparatus; chemical shifts are given in ppm from SiMe₄, with coupling constants in Hz. Mass spectra were determined with a VG-70EQ apparatus.

Compounds **3a,b** were commercially available. Compounds $3c^{10}$ and $3d^{11}$ were prepared according to literature methods.

2-Amino-N-methyl-N-(prop-2-ynyl)benzamide 4a. *N*-Methylpropargylamine (200 mg, 2.9 mmol) was added to a solution of **3a** (315 mg, 1.9 mmol) in dioxane (10 mL). The mixture was heated at reflux for 3 h, then poured in ice/water (50 mL), adjusted to pH 9 with 5% NaOH and extracted with Et₂O. The organic layer was dried over Na₂SO₄ and evaporated under reduced pressure. The crude product was chromatographed on silica with chloroform/methanol 10:1 as eluent to give **4a** (195 mg, 54%). Oil; ¹H-NMR (CDCl₃) δ 2.31 (1H, t, *J* 2.4), 3.09 (3H, s), 4.19 (2H, d, *J* 2.4), 4.40 (2H, br s, missing after deuteriation), 6.71 (1H, d, *J* 7.7), 6.73 (1H, dd, *J* 7.4, 7.7), 7.14-7.24 (2H, m); IR (nujol) 1620, 2120, 3280, 3350, 3450 cm⁻¹; MS *m/z* 188 (M⁺); Anal. Calcd. for C₁₁H₁₂N₂O: C, 70.19; H, 6.43; N, 14.88. Found: C, 70.3; H, 6.48; N, 15.01.

General procedure for preparation of anthranilamides 4b-d. *N*-Methylpropargylamine (3.6 mmol) was added to a solution of 3b-d (1.6 mmol) in DMF (8 mL). The mixture was heated at reflux for 3 h, then poured in ice/water (50 mL), adjusted to pH 9 with 5% NaOH and extracted with Et₂O. The organic layer was dried

over Na_2SO_4 and evaporated under reduced pressure. The crude product was chromatographed on silica with chloroform/methanol 10:1 as eluent for **b-c** and diethyl ether/light petroleum 10:1 for **c**, giving the pure products **4b-d**.

4b: (53%). Oil; ¹H-NMR (CDCl₃) δ 2.32 (1H, t, J 2.3), 3.10 (3H, s), 4.19 (2H, d, J 2.3), 4.36 (2H, br s, missing after deuteriation), 6.64 (1H, d, J 8.6), 7.11 (1H, dd, J 2.4, 8.6), 7.16 (1H, d, J 2.4); IR (nujol) 1620, 2110, 3290, 3350, 3460 cm⁻¹; MS *m/z* 222 (M⁺); Anal. Calcd. for C₁₁H₁₁ClN₂O; C, 59.33; H, 4.98; N, 12.58. Found: C, 59.26; H, 5.14; N, 12.53.

4c: (50%). Oil; ¹H-NMR (CDCl₃) δ 2.31 (1H, t, J 2.3), 3.10 (3H, s), 4.09 (4H, overlapping; after deuteriation: d, J 2.3), 6.66 (1H, dd, J 4.5, 9.2), 6.88-6.94 (2H, m); IR (nujol) 1625, 2120, 3295, 3350, 3450 cm⁻¹; MS: *m/z* 206 (M⁺); Anal. Calcd. for C₁₁H₁₁FN₂O: C, 64.07; H, 5.38; N, 13.58. Found: C, 64.11; H, 5.47; N, 13.48.

4d: (44%). Oil; ¹H-NMR (CDCl₃) δ 2.39 (1H, t, J 2.3), 3.16 (3H, s), 4.24 (2H, d, J 2.3), 5.38 (2H, br s, missing after deuteriation), 6.72 (1H, d, J 9.0), 8.08 (1H, dd, J 2.6, 9.0), 8.21 (1H, d, J 2.6); IR (nujol) 1620, 2110, 3260, 3390, 3490 cm⁻¹; MS *m/z* 233 (M⁺); Anal. Calcd. for C₁₁H₁₁N₃O₃: C, 56.65; H, 4.75; N, 18.02. Found: C, 56.74; H, 4.91; N, 18.13.

General procedure for preparation of 5-methyl[1,2,3]triazolo[1,5-*a*][1,4]benzodiazepin-6(4H)-ones 6a-d. NaNO₂ (1.2 mmol) was added portionwise to a solution of 4a-d (0.6 mmol) in 1N aq HCl (4 mL) and glacial AcOH (7 mL) under stirring and cooling at 0 °C. After stirring for 40 min, the mixture was treated with cold Et₂O (16 mL) and NaN₃ (3.5 mmol) was added portionwise under vigorous stirring and ice-cooling for 3 h. The organic layer was separated, washed with aq NaHCO₃ and dried over Na₂SO₄. The solvent was removed under reduced pressure to give 6a-d.

6a: (41%). M.p. 169-171 °C (diisopropyl ether); ¹H-NMR (CDCl₃) δ 3.21 (3H, s), 4.42 (2H, s), 7.55 (1H, ddd, *J* 1.2, 7.7, 7.8), 7.68 (1H, ddd, *J* 1.5, 7.6, 7.7), 7.74 (1H, s), 7.98 (1H, dd, *J* 1.2, 7.6), 8.07 (1H, dd, *J* 1.5, 7.8); ¹³C-NMR (CDCl₃) δ 36.56 (q), 42.15 (t), 122.92 (d), 127.65 (s), 129.48 (d), 131.01 (d), 132.65 (d), 133.02 (s), 133.22 (d), 134.73 (s), 166.72 (s); IR (nujol) 1645 cm⁻¹; MS *m/z* 214 (35, M⁺), 186 (44), 185 (58), 143 (73), 115 (100%); Anal. Calcd. for C₁₁H₁₀N₄O; C, 61.67; H, 4.71; N, 26.15. Found: C, 61.62; H, 4.84; N, 26.23.

6b: (55%). M.p. 146-148 °C (diisopropyl ether); ¹H-NMR (CDCl₃) δ 3.25 (3H, s), 4.47 (2H, s), 7.67 (1H, dd, *J* 2.4, 8.7), 7.77 (1H, s), 7.98 (1H, d, *J* 8.7), 8.09 (1H, d, *J* 2.4); ¹³C-NMR (CDCl₃) δ 36.55 (q), 42.09 (t), 124.34 (d), 128.88 (s), 131.19 (d), 131.49 (s), 132.54 (d), 133.34 (d), 134.51 (s), 135.63 (s), 165.42 (s); IR (nujol) 1640 cm⁻¹; MS *m/z* 250 (14, M⁺+2) 248 (39, M⁺), 222 (17), 221 (38), 220 (52), 219 (100),178 (44), 177 (72), 151 (21), 149 (50), 114 (71%); Anal. Calcd. for C₁₁H₉ClN₄O; C, 53.13; H, 3.65; N, 22.53. Found: C, 53.20; H, 3.58; N, 22.58.

6c: (43%). M.p. 155-156 °C (diisopropyl ether); ¹H-NMR (CDCl₃) δ 3.25 (3H, s), 4.47 (2H, s), 7.42 (1H, ddd, *J* 2.9, 7.3, 8.9), 7.77 (1H, s), 7.80 (1H, dd, *J* 2.9, 8.9), 8.02 (1H, dd, *J* 4.8, 8.9); ¹³C-NMR (CDCl₃) δ 36.25 (q), 41.70 (t), 118.82 (d), 120.24 (d), 124.73 (d), 125.45 (s), 126.67 (s), 128.23 (s), 130.63 (d), 133.99

(s), 163.79 (s); IR (nujol) 1635 cm⁻¹; MS m/z 232 (35, M⁺), 204 (44), 203 (100), 161 (55), 133 (94%); Anal.
Calcd. for C₁₁H₉FN₄O; C, 56.90; H, 3.91; N, 24.13. Found: C, 56.99; H, 4.03; N, 24.27.

6d: (47%). M.p. 197-198 °C (diisopropyl ether); ¹H-NMR (CDCl₃) δ 3.30 (3H, s), 4.54 (2H, s), 7.26 (1H, d, *J* 8.9), 7.83 (1H, s), 8.55 (1H, dd, *J* 2.6, 8.9), 9.00 (1H, d, *J* 2.6); ¹³C-NMR (CDCl₃) δ 36.97 (q), 41.98 (t), 124.28 (d), 127.74 (d), 128.83 (d), 131.70 (d), 134.86 (s), 136.89 (s), 145.76 (s), 147.88 (s), 164.63 (s); IR (nujol) 1650 cm⁻¹; MS *m*/*z* 259 (51, M⁺), 231 (100), 230 (86), 188 (91), 142 (62), 114 (35%); Anal. Calcd. for C₁₁H₉N₅O₃; C, 50.97; H, 3.50; N, 27.02. Found: C, 50.88; H, 3.43; N, 27.17.

8-Amino-5-methyl[1,2,3]triazolo[1,5-*a***][1,4]benzodiazepin-6(4***H***)-one 6e. A mixture of 10% Pd/C (100 mg) and 6d (103 mg. 0.4 mmol) in MeOH (80 mL) and CHCl₃ (80 ml) was stirred under H₂ for 2 h. After filtration through celite, the solvent was evaporated under reduced pressure. The crude product was chromatographed on silica with chloroform/methanol 10:1 as eluent to give 6e (89 mg. 98%). M.p. 190-192 °C (diisopropyl ether): ¹H-NMR (DMSO_{-d6}) \delta 3.06 (3H, s), 4.51 (2H, s), 5.76 (2H, br s, missing after deuteriation), 6.91 (1H, dd,** *J* **2.4, 8.7), 7.06 (1H, d,** *J* **2.4), 7.54 (1H, d,** *J* **8.7), 7.83 (1H, s); IR (nujol) 1630, 3215, 3330 cm⁻¹; MS** *m/z* **229 (100, M⁺), 201 (47), 200 (69), 174 (20), 158 (43), 130 (30%); Anal. Calcd. for C₁₁H₁₁N₅O: C, 57.63; H, 4.84; N, 30.55. Found: C, 57.53; H, 4.91; N, 30.70.**

Acknowledgements: We are grateful to MURST and CNR for financial support.

References

- 1. Vida, J.A. in Medicinal Chemistry, Wolf, M.W. and Burger, A. Eds; Wiley, New York, 1981, p. 787.
- Landquist, J.K. in *Comprehensive Heterocylic Chemistry*, Katritzky, A.R. and Rees, C.W. Eds; Pergamon Press, Oxford, 1984, Vol. 1, Ch. 1/06.
- 3. Sharp, J.T. in *Comprehensive Heterocyclic Chemistry*, Katritzky, A.R. and Rees, C.W. Eds; Pergamon Press, Oxford, 1984, Vol. 7, Ch. 5/18.
- 4. Hester, J.B., Jr. in Antianxiety Agents, Berger, J.G. Ed.; Wiley, New York, 1986, pp. 51-126.
- Fryer, R.I. in *Comprehensive Medicinal Chemistry*, Hansch, C. Ed; Pergamon Press, New York, 1990, Vol. 3, pp. 539-566.
- 6. The Merck Index, 12th edition, Budavari, S. Ed; Merck & Co., Whitehouse Station, New Jersey, 1996.
- 7. Fröstl, W.: Maître, L. Pharmacopsych. 1989, 22, 54.
- 8. Broggini, G.; Zecchi, G.; Molteni, G. Gazz. Chim. Ital. 1997, 127, 809.
- 9. Broggini, G.; Garanti, L.; Molteni, G.; Zecchi, G. J. Chem. Res. 1997, 380 (S), 2215 (M).
- 10. Coppola, G.M. Synthesis 1980, 505.
- 11. Rupe, H.; Kersten, L. Helv. Chim. Acta, 1926, 9, 578.